Lars Soerensen - Novo Nordisk CEO

NONOF Stock  USD 126.50  0.95  0.75%   

CEO

Mr. Lars Rebien Soerensen no longer serves as Chief Executive Officer and President at Novo Nordisk AS effective as of by the end of 2016 . He was CEO since November 2000 and he has served as President of the Company since April 2015. He also served as President of the Company from November 2000 until January 30 2014. He joined the Company Enzymes Marketing in 1982. Over the years he was stationed in several countries including the Middle East and the United States. He was appointed Member of Corporationrationrate Management in May 1994 and was given responsibility for Health Care within Corporationrationrate Management in December 1994. He is Vice Chairman of the Boards of Directors of Carlsberg AS. He received the French award Chevalier de lOrdre National de la Legion dHonneur in 2005. Since October 2007 he was Adjunct Professor at the Faculty of Life Sciences of Koebenhavns Universitet . He holds a MS degree in Forestry from Koebenhavns Universitet from 1981 and a BS degree in International Economics from Copenhagen Business School from 1983. since 2015.
Age 60
Tenure 9 years
Phone45 44 44 88 88
Webhttps://www.novonordisk.com

Novo Nordisk Management Efficiency

The company has return on total asset (ROA) of 0.2169 % which means that it generated a profit of $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.72 %, meaning that it generated $0.72 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. Novo Nordisk AS has a current ratio of 0.92, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

CEO Age

Paul PerreaultCSL Limited
60
Lars JoergensenNovo Nordisk AS
54
Leonard SchleiferRegeneron Pharmaceuticals
65
Paul PerreaultCSL
60
MD FASNVertex Pharmaceuticals
50
Lars JorgensenNovo Nordisk AS
58
Robert MoscatoModerna
41
David DomzalskiVyne Therapeutics
57
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. NOVO NORDISK is traded on OTC Exchange in the United States. Novo Nordisk AS [NONOF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Novo Nordisk AS Leadership Team

Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
Soeren Pedersen, Director, Employee Representative
Doug Langa, Senior Vice President Head of North America Operations and Presidentident of Novo Nordisk Inc.
Jakob Riis, Executive VP of China, Pacific and Marketing and Member of Executive Management
Kasim Kutay, Director
Jesper Brandgaard, CFO, Executive Vice President
Sylvie Gregoire, Director
Mette Jensen, Director, Employee Representative
Mary Szela, Director
Jerzy Gruhn, Executive Vice President Europe
Douglas Langa, Head VP
Eivind Kolding, Director
Kasper Poulsen, Head of Investor Relations, Corporate Vice President
Thomas Rantzau, Director, Employee Representative
Lars Jorgensen, CEO Pres
Karsten Knudsen, CFO, Executive Vice President
Lars Joergensen, Executive Vice President CIO
Helge Lund, Director
Martin Lange, Head VP
Maziar Doustdar, Executive Vice President International Operations
Brian Daniels, Director
Goran Ando, Chairman of the Board
Martin Mackay, Director
Jeppe Christiansen, Vice Chairman of the Board
Bruno Angelici, Independent Director
Liselotte Hyveled, Director, Employee Representative
Anne Kverneland, Director, Employee Representative
Kaare Schultz, President COO
Liz Hewitt, Independent Director
Jesper Hoeiland, Executive Vice President US
Ludovic Helfgott, Executive Vice President of Biopharm
Camilla Sylvest, Executive Vice President Commercial Strategy & Corporate Affairs
Mads Thomsen, Chief Science Officer, Executive VP and Member of Executive Management
Andreas Fibig, Director
Monique Carter, Head VP
Peter Ankersen, Corporate Vice President & Head of Investor Relations
Laurence Debroux, Director
Lars Soerensen, CEO
Marcus Schindler, Head EVP
Stig Stroebaek, Director, Employee Representative
Henrik Wulff, Executive Vice President Product Supply
Thomas Koestler, Independent Director
Lars Green, Executive Vice President Business Services & Compliance

Novo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Novo Pink Sheet analysis

When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Global Correlations
Find global opportunities by holding instruments from different markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.